OOS Investigations: Decision-Making in Practice and FDA Expectations for 2026‎ |‎ ‎How to interpret results, recognize signals, and align with current FDA expectations

OOS results are rarely just laboratory events. They test how decisions are made, how information is interpreted, and how well quality systems respond when something does not go as expected.

In many organizations, the initial response to an out-of-specification result follows a familiar path: retesting begins, assumptions are made early, and conclusions are shaped before the full picture is understood. On the surface, the investigation may appear structured. But under closer review, gaps often emerge in how results were evaluated, how potential causes were considered, and how final decisions were justified.

Regulatory expectations in this area continue to evolve. Inspectors are no longer focused only on whether an investigation was completed, but on how decisions were made at each step, how scientific reasoning was applied, and whether the outcome reflects a clear and consistent approach. Subtle signals, overlooked trends, and undocumented assumptions are increasingly becoming points of concern.

This session takes a closer look at how OOS investigations unfold in practice: from the moment a result is identified to the way conclusions are formed and documented. Through practical discussion, the focus will be on interpreting results with clarity, recognizing when deeper evaluation is needed, and aligning investigation decisions with current FDA expectations.

AREAS COVERED:

• How OOS results are initially assessed and why early decisions often shape the entire investigation
• Recognizing meaningful signals, trends, and inconsistencies that may not be immediately obvious
• Approaches to evaluating laboratory error versus potential process-related causes
• How investigation pathways are structured, including when to expand beyond the laboratory
• Documentation practices that reflect clear thinking, scientific reasoning, and consistent decision-making
• FDA expectations for OOS investigations, including key principles from 21 CFR Part 211 and related guidance

WHO SHOULD ATTEND:

• Quality Assurance Departments
• Quality Control Departments
• Manufacturing Departments
• Operations Departments
• Research and Development Departments
• Regulatory Affairs Departments
• Compliance Departments
• Validation Departments
• Technical Services
• Auditing/Internal Auditors
• Laboratory Analysts
• CAPA Coordinators
• Site Heads and Directors of Quality

Course Director: MEREDITH CRABTREE

Meredith Crabtree has over 30 years’ experience in regulated industries, ranging from Blood, Plasma, Tissue, Laboratory, Pharma, Medical Device, Cosmetics, Supplements, and Animal Health. This includes manufacturing, packaging, labelling and distribution operations. Meredith is the owner of MLKC Consulting is s a Quality Consultant specializing in product label reviews, 3rd party inspections, Consent Decree and Recall support. She also performs regulatory assessments and Quality trainings.